Citius Oncology prices $9 million public offering at $1.32 per share

Citius Oncology Inc. (NASDAQ: CTOR) announced the pricing of its public offering of 6,818,182 shares of common stock and warrants at $1.32 per share. The offering is expected to generate approximately $9 million in gross proceeds before deducting placement agent fees and other expenses.

The warrants will have an exercise price of $1.32 per share, will be immediately exercisable upon issuance, and will expire five years from the date of issuance. Maxim Group LLC is serving as the sole placement agent for the offering.

The company plans to use the net proceeds primarily to support the commercialization of LYMPHIR, including milestone, royalty, or other payments pursuant to existing license agreements, as well as for working capital and general corporate purposes. The offering is expected to close on or about July 17, 2025, subject to customary closing conditions.

The securities are being offered pursuant to a registration statement on Form S-1 that was filed with the U.S. Securities and Exchange Commission on July 14, 2025, and declared effective on July 16, 2025.

Citius Oncology is a majority-owned subsidiary of Citius Pharmaceuticals Inc. (NASDAQ: CTXR), with Citius Pharmaceuticals owning 92% of the company. LYMPHIR was approved by the FDA in August 2024 for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma who had at least one prior systemic therapy.

You May Also Be Interested In

• Karman Line Acquisition prices $200M IPO on Nasdaq
• Skyline Builders acquires two Nevada gold and silver properties
• Andersen Group launches secondary offering of 4.28M shares